ReviewRheumatology (Oxford, England)2024
Lymphadenopathy in the rheumatology practice: a pragmatic approach.
Review in Rheumatology (Oxford, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman disease.Internal medicine journal · 2026Guideline
- Brazilian Academy of Neurology recommendations for diagnosis, management, and treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).Arquivos de neuro-psiquiatria · 2025Guideline
- The EULAR points to consider regarding the development of criteria for the assessment of the disease activity in adult-onset Still's disease.EULAR rheumatology open · 2026Article
- The clinical significance of serum complement fibroblast growth factor 21 in patients with rheumatoid arthritis.BMC immunology · 2026Article
- A Case of Systemic Lupus Erythematosus Initially Presenting With Generalized Lymphadenopathy: A Diagnostic Challenge.Cureus · 2026Article
- Diagnostic Value of 18F-FDG PET/CT in Guiding Biopsy Decisions and Differentiating Infectious, Inflammatory and Malignant Lesions.Journal of clinical medicine · 2026Article
- The Role of Imaging Techniques in the Evaluation of Extraglandular Manifestations in Patients with Sjögren's Syndrome.Diagnostics (Basel, Switzerland) · 2026Review
- Issues and missed opportunities in lymph node assessment after neoadjuvant chemotherapy.The Journal of pathology · 2025Review
- Lymphoproliferative Disorders Mimicking Rheumatologic Disease: A Clinical Reasoning Perspective.Current allergy and asthma reports · 2025Review
- IgG4-related disease with subcutaneous involvement and the associated diagnostic challenges with MRI.Skeletal radiology · 2025Article
- Langerhans cells infiltration in lymph nodes of patients with systemic lupus erythematosus.Lupus science & medicine · 2025Article
- Lymphadenopathy and synovial hyperplasia are associated with sepsis risk in an experimental model of rheumatoid arthritis.Frontiers in immunology · 2025Article
- Development and implementation of the International AIDA Network Castleman's disease registry.Frontiers in medicine · 2025Article
- Lymph nodes as gatekeepers of autoimmune diseases.RMD open · 2024Review
- Identifying Castleman disease from non-clonal inflammatory causes of generalized lymphadenopathy.Hematology. American Society of Hematology. Education Program · 2024Review
- Educational Case: Rosai-Dorfman disease mimicking metastatic carcinoma.Academic pathologyArticle
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
Abstract
Lymphadenopathy is a common clinical finding and diagnostic challenge within general medicine and rheumatology practice. It may represent a primary manifestation of an underlying immune-mediated disease or indicate an infectious or neoplastic complication requiring differing management. Evaluating lymphadenopathy is of particular relevance in rheumatology, given that lymph node enlargement is a common finding within the clinical spectrum of several well-known rheumatologic disorders including RA, SLE and SS. In addition, lymphadenopathy represents a hallmark manifestation of rare immunological diseases such as Castleman disease and IgG4-related disease that must be considered in the differential diagnosis because effective targeted treatments can now impact the prognosis of these conditions. In this review we present an overview of the clinical significance of lymphadenopathy in common and rare rheumatologic diseases and propose a practical approach to lymphadenopathy in the rheumatology practice. Differential diagnosis of Castleman disease and therapeutic options for this condition of increasing rheumatologic interest will be discussed in detail.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.